Cancer, a common and devastating disease process in both people and animals, can be difficult to detect until it is in relatively advanced stages – when it is more challenging to treat and control.  Rametrix Technologies, Inc. is now leveraging its platform technology – Rametrix Urine Molecular Fingerprinting® – in the fight against cancer, focusing on aiding accurate diagnosis and assessing how well treatments are working.  Several current projects are aimed at detection of cancer at earlier stages of development, when it may be more effectively controlled.